Status:
COMPLETED
Dendritic Cells in Lung Cancer
Lead Sponsor:
Herlev Hospital
Collaborating Sponsors:
University of Copenhagen
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced ...
Detailed Description
Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced ...
Eligibility Criteria
Inclusion
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00442754
Start Date
December 1 2006
End Date
November 1 2009
Last Update
March 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev University Hospital
Copenhagen, Denmark, DK-2730 Herlev